Valuation: Harrow, Inc.

Market Cap 1.47B 1.29B 1.2B 1.1B 2.07B 140B 2.1B 14.21B 5.56B 69.44B 5.5B 5.38B 240B P/E 2026 *
169x
P/E 2027 * 16.8x
Enterprise Value 1.47B 1.29B 1.2B 1.1B 2.07B 140B 2.1B 14.21B 5.56B 69.44B 5.5B 5.38B 240B EV / Sales 2026 *
4.21x
EV / Sales 2027 * 2.83x
Free-Float
84.53%
Yield 2026 *
-
Yield 2027 * -
1 day+4.97%
1 week-10.04%
Current month-7.42%
1 month-6.54%
3 months-2.87%
6 months-7.68%
Current year-19.76%
1 week 36.25
Extreme 36.25
42.8
1 month 36.25
Extreme 36.25
47.5
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 2011-12-16
President 43 2025-08-20
Compliance Officer - 2023-09-30
Director TitleAgeSince
Chairman 53 2021-08-18
Director/Board Member 57 2022-03-30
Director/Board Member 71 2024-01-25
Date Insider Type Main position Quantity % Market Cap.
6/18/26 Free

Director

5,248 0.0141%
6/18/26 Free

Director

5,248 0.0141%
6/18/26 Free

Director

5,248 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
+4.97%-10.04%+12.79%+83.31% 1.46B
+1.93%+3.85%+51.05%+166.24% 1,089B
+0.29%+6.43%+60.47%+52.87% 643B
+2.45%+2.77%+39.61%+74.48% 465B
-0.27%+10.26%+41.23%+35.44% 359B
-0.17%+3.81%+37.37%+42.88% 303B
+1.39%+3.23%+17.51%+17.22% 267B
+0.09%+4.90%-3.39%-38.63% 226B
+4.48%+7.33%+30.47%+66.31% 212B
+2.91%+3.10%+18.84%+74.76% 167B
Average +1.41%+3.56%+30.60%+57.49% 373.26B
Weighted average by Cap. +0.85%+5.13%+40.87%+79.79%

Financials

2026 *2027 *
Net sales 348M 306M 285M 262M 491M 33.29B 499M 3.38B 1.32B 16.51B 1.31B 1.28B 57.04B 517M 454M 423M 389M 729M 49.44B 742M 5.02B 1.96B 24.52B 1.94B 1.9B 84.71B
Net income 9.18M 8.06M 7.5M 6.9M 12.94M 877M 13.16M 89.02M 34.84M 435M 34.47M 33.72M 1.5B 93.99M 82.48M 76.81M 70.65M 132M 8.98B 135M 911M 357M 4.45B 353M 345M 15.39B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
26-07-28 US$39.32 +4.97% 569,628
26-07-27 US$37.46 -2.57% 516,682
26-07-24 US$38.45 -8.19% 888,661
26-07-23 US$41.88 -2.22% 366,233
26-07-22 US$42.83 -2.01% 382,762
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
39.32USD
Average target price
67.75USD
Spread / Average Target
+72.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock